The year 2025 is poised to be a landmark year for the clinical implementation of brain-computer interface (BCI) technology in China. Major cities like Beijing and Shanghai are intensifying the testing of invasive BCI products. Notably, Shanghai Huashan Hospital and Beijing Xuanwu Hospital have embarked on clinical cohort studies designed to ascertain the safety and efficacy of implantable BCI solutions. Tsinghua University's NEO device aims to enroll spinal cord injury patients for trials within the year, with the ultimate goal of securing market authorization. Furthermore, the "Brain One" has successfully completed its first batch of human implants, and Fudan University has established a dedicated research center to facilitate the translational application of BCI technology. Additionally, the National Healthcare Security Administration has initiated relevant pricing projects. Despite notable advancements, invasive BCIs continue to confront challenges related to biocompatibility and ethical standards, necessitating further technological advancements to facilitate widespread adoption.